The settlement removes near-term overhang from this specific ANDA filer but establishes a clear generic entry timeline for DOJOLVI. Monitor progress of remaining ANDA litigations and any FTC/DOJ challenge to the settlement. The 2033 generic entry date is distant, so near-term revenue impact is minimal, but the settlement signals that patent protection may not extend beyond that window.
RARE drugs
RARE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $26.80entry
- T+1 · 3mo ago +0.22%α −0.03% · $26.86
- T+5 · 3mo ago −4.89%α −4.48% · $25.49
- T+20 · 2mo ago −46.60%α −45.55% · $14.31
- T+60 · 13d ago −34.79%α −34.66% · $17.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ultragenyx settled patent litigation with Esjay Pharma over generic DOJOLVI (triheptanoin). Esjay gets a non-exclusive, royalty-free license to market its generic version starting January 1, 2033 (extended to July 1, 2033 if pediatric exclusivity is granted). The settlement removes near-term generic risk but sets a definitive loss of exclusivity date, while litigation against other ANDA filers remains pending. No financial terms were disclosed, and the agreement is subject to FTC/DOJ review.
Key Facts
- Ultragenyx settled DOJOLVI patent litigation with Esjay Pharma on August 7, 2026.
- Esjay receives a non-exclusive, royalty-free license to market generic DOJOLVI starting January 1, 2033 (or July 1, 2033 if pediatric exclusivity is granted).
- Litigation against other ANDA filers for DOJOLVI remains pending in the District of New Jersey.
- The settlement agreement will be submitted to the FTC and DOJ as required by law.
- No financial terms of the settlement were disclosed.
Financial Impact
No financial terms disclosed; settlement removes litigation uncertainty but establishes a definitive generic entry date of January 1, 2033 (or July 1, 2033 with pediatric exclusivity).
Risk Factors
- Remaining ANDA litigations could result in earlier generic entry if not settled on similar terms.
- FTC or DOJ could challenge the settlement agreement as anticompetitive.
- Loss of exclusivity for DOJOLVI in 2033 will materially reduce revenue from the product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343525 |
| Document: 0001193125-26-343525-index.html | 0001193125-26-343525 |
| Document: 0001193125-26-343525.txt | 0001193125-26-343525 |
Track record
22 reports on RARE
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers